医疗专业人员

下面列出了当前开展的临床试验。

根据地点、状态和其他条件对此研究列表进行过滤。

1. A Study of Noninvasive Hemoglobin Monitoring in Pediatric Patients Undergoing Orthopedic Surgery

   Rochester, Minn.

   The purposes of this study are to validate noninvasive hemoglobin monitoring in postoperative orthopedic pediatric patients, to evaluate patient, parent, and provider preference of noninvasive hemoglobin monitoring compared to invasive blood draw, and to evaluate cost effectiveness of noninvasive monitoring in comparison to invasive blood draws.

2. Multi-Center Prospective Validation Study of VTE Risk Prediction Tool in Trauma Patients

   Rochester, Minn.

   Almost one-half million people suffer venous thromboembolism annually in the United States, and one-third die from this disease. Massive bleeding from injury accounts for half of early deaths after trauma. This study aims to prevent the deaths and suffering associated with venous thromboembolism and bleeding by identifying the individual person at high risk of these complications in order to take preventive measures.

3. A Study to Establish a Living Breast Organoid Biobank for Translational Research

   Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

   Researchers at Mayo Clinic are developing a Biobank of adult stem cell-rich breast organoids, a new research resource to facilitate normal and cancer stem cell research. Subjects in the Biobank will provide samples of excess breast tissue, complete a health questionnaire, and allow access to medical records now and in the future. The Biobank serves as a library for researchers; instead of having to look for volunteers for each new project, researchers can use samples from the Biobank as well as share information already collected.

4. Registry for the EVolution Of LUng Cancer Therapy Implementation and Outcomes Now

   Rochester, Minn.

   REVOLUTION will be a US multicenter observational registry in scope and governed by a steering committee of approximately 8 experts in NSCLC and outcomes research. The primary goal of the registry is characterizing patterns of use for NSCLC therapy. REVOLUTION will be a multicenter registry enrolling approximately 2,500 patients. Additional patients limited to those with EGFR mutations may be enrolled following the initial study period as needed to ensure adequate sample sizes needed to examine primary questions of interest in the EGFR mutant population. Patients will be enrolled over a three year period across approximately 25 geographically diverse academic as well as community based sites within the US. The five year follow-up period will ensure robust survival data for correlations with clinical, tumor, and treatment variables.

   The target of 2,500 patients is meant to ensure adequate numbers of NSCLC patients with particular characteristics of interest including patients with adenocarcinoma, and EGFR mutations and effectively evaluate these patients with respect to key outcomes of interest including overall survival, time to progression, stage at progression, secondary metastases including brain metastases (at diagnosis and progression), comorbidity burden, and performance status at index date.

   The study design allows a cross-sectional perspective with collection of detailed patient and clinical characteristics at enrollment followed by longitudinal assessment of clinician and patient-reported endpoints every three months. Centralized follow-up will be conducted by having sites upload patient data following each visit via the web-based data system, with patients who do not show up for site visits being contacted via telephone by the Duke Clinical Research Institute (DCRI) call center. Site recruitment and patient enrollment will be weighted based upon provider specialty and ability to enroll patients with NSCLC with the specified inclusion criteria.

5. IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

   Jacksonville, Fla.

   The purpose of this study is for IMC-F106C plus nivolumab compared to standard nivolumab regimens in HLA-A*02:01-positive participants with previously untreated advanced melanoma.

6. A Study of Mesenchymal Stem Cell (MSC) Adherence and Vessel Wall Penetration Following Intra-arterial Delivery Subsequent to Controlled Balloon Angioplasty

   Jacksonville, Fla.

   The purpose of this study is to determine the amount of MSCs that adhere to predetermined areas of arterial wall following balloon angioplasty vs no intervention, and to characterize the effect of intra-arterial injection of MSCs on predetermined areas of arterial wall via transcriptome analysis.

7. A Study Evaluating the Prevalence, Incidence and Predictors for Development of the Impulse Control Disorders in Patients with Prolactinomas Treated with Dopamine Agonist Therapy

   Rochester, Minn., Jacksonville, Fla.

   The purpose of this study is to establish incidence and prevalence of Impulse Control Disorders (ICDs) in patients with prolactinomas treated with dopamine agonists (DA), to determine the predictors of ICD development, and to establish a predictor scoring system that could be subsequently validated and applied prior to initiation of DA.

8. A Study of Long-term Symptom Improvement and Recurrence After Operative Management of Median Arcuate Ligament Syndrome

   Rochester, Minn.

   The purpose of this study is to evaluate long-term symptom resolution and quality of life improvements after operative management of median arcurate ligament syndrome (MALS).

9. Innovative CAR-TIL immunotherapy against melanoma

   Jacksonville, Fla.

   The chimeric antigen receptor (CAR) T-cell therapy is a revolutionary cellular immunotherapy strategy that has transformed the treatment of B cell malignancies by engineering T cells to recognize B cell specific tumor markers; however, attempts to treat solid tumors with CAR T-cells have identified unique challenges that have rendered CAR T cells less effective against these tumors. Conventional CARs are designed to target tumor-associated antigens, but antigenic heterogeneity and the variable nature of surface antigen expression provide escape mechanisms for solid tumors from CAR T-cell attack. [1, 2] The solid tumor stroma acts as an immunosuppressive cloud that impedes the homing of peripheral CAR T-cells into the tumor microenvironment (TME). The hostile TME can also drive CAR T-cells to functional exhaustion and metabolic dysfunction, thus blunting the therapeutic efficacy of CAR T-cells.[3] Oncolytic viruses or radiation that generate local inflammation in the TME have been shown to promote T cell homing and infiltration [4] but do not address the exhaustion of tumor infiltrating lymphocytes (TILs). The PD-1/PD-L1 cascade allows tumors to evade the immune system by suppressing T cell function within the TME. [5, 6] An ideal adoptive cellular therapy must possess the ability to not only return to the site of the tumor but must also retain cytotoxic potential after a recognition event. We present here a CAR design that allows PD-1 to recognize PD-L1 on the tumor; however, the intracellular CAR design is one that results in T cell activation as opposed to inhibition. We hypothesize that targeting melanoma with a PD-1 (MC9324) CAR TIL therapy would capitalize on the tumor homing machinery of the TIL to drive the CAR TIL to the tumor where engagement of the PD-1 domain of the CAR with PD-L1 on the tumor cell would result in T cell cytotoxic killing.

10. A Study to Analyze Gender Congruence After Gender Confirmation Surgery

    Rochester, Minn.

    The purpose of this study is to assess the success and effectiveness of gender confirmation surgeries on eliminating gender incongruence and improving life satisfaction, and compare patient’s status with the preoperative results.